Obesity Market Snapshot: Marketing Partners Giving Obesity The Slow Goodbye
Executive Summary
Takeda's split from Contrave partner Orexigen may be followed by Eisai leaving Arena; the big pharma is already pulling back reps from Belviq, though Arena has high hopes for a new extended-release formulation.